Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod for MG Exacerbation
NCT06860633Phase 4Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 4 trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by University of Colorado Denver. Started Mar 2025; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06860633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860633.